Literature DB >> 2168767

Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines.

M Oguro1, Y Seki, K Okada, T Andoh.   

Abstract

Collateral drug sensitivity was induced in CPT-11-resistant cell lines (CPT-K and T). Ten of the 19 kinds of antineoplastic agents (especially, 5 of 6 kinds of DNA topoisomerase II inhibiting agents) were effective in inducing collateral drug sensitivity. Alteration of DNA topoisomerase I seemed to be unrelated to acquisition of multidrug resistance.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2168767     DOI： 10.1016/0753-3322(90)90026-6

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN： 0753-3322            Impact factor:   6.529


  10 in total

1.  Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.

Authors:  Kathryn M Camacho; Sunny Kumar; Stefano Menegatti; Douglas R Vogus; Aaron C Anselmo; Samir Mitragotri
Journal:  J Control Release       Date:  2015-04-25       Impact factor: 9.776

Review 2.  Topoisomerase I in multiple drug resistance.

Authors:  A Pessina
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

3.  Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs.

Authors:  Wanyi Tai; Ran Mo; Yue Lu; Tianyue Jiang; Zhen Gu
Journal:  Biomaterials       Date:  2014-05-27       Impact factor: 12.479

Review 4.  Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?

Authors:  Richard Callaghan; Frederick Luk; Mary Bebawy
Journal:  Drug Metab Dispos       Date:  2014-02-03       Impact factor: 3.922

5.  A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.

Authors:  Vinicius Ernani; Rahat Jahan; Lynette M Smith; Alissa S Marr; Sarah E Kimbrough; Mary E Kos; Jolene Tijerina; Shannon Pivovar; Imayavaramban Lakshmanan; Marsha Ketcham; Sanchita Rauth; Kavita Mallya; Mohd W Nasser; Maneesh Jain; Anne Kessinger; Surinder K Batra; Apar Kishor Ganti
Journal:  Cancer Treat Res Commun       Date:  2019-10-07

6.  Low-molecular-weight polymer-drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations.

Authors:  Kathryn M Camacho; Stefano Menegatti; Samir Mitragotri
Journal:  Nanomedicine (Lond)       Date:  2016-04-15       Impact factor: 5.307

7.  Topoisomerase I inhibitors and drug resistance.

Authors:  R E Parchment; A Pessina
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

8.  In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.

Authors:  P B Jensen; B Holm; M Sorensen; I J Christensen; M Sehested
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants.

Authors:  V Pavillard; D Kherfellah; S Richard; J Robert; D Montaudon
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

10.  Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.

Authors:  M Sorensen; M Sehested; P B Jensen
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.